NLS Pharmaceutics Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0523961370
USD
3.64
0.03 (0.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

31.43 k

Shareholding (Dec 2024)

FII

0.11%

Held by 2 FIIs

DII

99.87%

Held by 0 DIIs

Promoter

0.00%

How big is NLS Pharmaceutics Ltd.?

22-Jun-2025

As of Jun 18, NLS Pharmaceutics Ltd. has a market capitalization of 8.42 million, classifying it as a Micro Cap company. There is no valid financial data available for net sales or net profit for the latest four quarters, with shareholder's funds at 1.41 million and total assets of 2.23 million as of December 2024.

Market Cap: As of Jun 18, NLS Pharmaceutics Ltd. has a market capitalization of 8.42 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: As of December 2024, the company has shareholder's funds of 1.41 million and total assets amounting to 2.23 million.

Read More

What does NLS Pharmaceutics Ltd. do?

22-Jun-2025

NLS Pharmaceutics Ltd. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with a market cap of USD 8.42 million. It is currently loss-making, with key metrics indicating a negative return on equity and no dividend yield.

Overview: <BR>NLS Pharmaceutics Ltd. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Market cap: USD 8.42 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.18 <BR>Return on Equity: -265.72% <BR>Price to Book: 5.99 <BR><BR>Contact Details: <BR>No Company Details Available.

Read More

Is NLS Pharmaceutics Ltd. technically bullish or bearish?

25-Jun-2025

As of June 17, 2025, the technical trend is mildly bullish, supported by weekly indicators like MACD and Bollinger Bands, despite some conflicting signals from daily moving averages and monthly indicators.

As of 17 June 2025, the technical trend has changed from sideways to mildly bullish. The current stance is mildly bullish, supported by the weekly MACD and Bollinger Bands indicating a bullish sentiment, despite the daily moving averages showing a mildly bearish position. The KST is bullish on the weekly timeframe, while the monthly indicators present a mixed outlook with some bearish signals. The Dow Theory reflects a mildly bullish stance on the monthly chart, and the OBV is bullish on the monthly as well. Overall, while there are some conflicting signals, the prevailing trend is mildly bullish.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 7 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.18

stock-summary
Return on Equity

-265.72%

stock-summary
Price to Book

5.18

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-81.43%
0%
-81.43%
6 Months
-82.5%
0%
-82.5%
1 Year
-83.82%
0%
-83.82%
2 Years
-98.35%
0%
-98.35%
3 Years
-99.05%
0%
-99.05%
4 Years
-99.32%
0%
-99.32%
5 Years
0%
0%
0.0%

NLS Pharmaceutics Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
2.53%
EBIT to Interest (avg)
-7.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.18
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
9.32%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
6.02
EV to EBIT
-1.87
EV to EBITDA
-1.87
EV to Capital Employed
-6.80
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-265.72%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 1 Schemes (0.01%)

Foreign Institutions

Held by 2 Foreign Institutions (0.11%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by NLS Pharmaceutics Ltd."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is -38.66% vs -310.34% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.50",
          "val2": "-11.90",
          "chgp": "-30.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.50",
          "val2": "-11.90",
          "chgp": "-38.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-15.50
-11.90
-30.25%
Interest
0.10
0.10
Exceptional Items
-0.90
0.00
Consolidate Net Profit
-16.50
-11.90
-38.66%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales

YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is -38.66% vs -310.34% in Dec 2021

stock-summaryCompany CV
About NLS Pharmaceutics Ltd. stock-summary
stock-summary
NLS Pharmaceutics Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available